Cargando…

Characterization of a vraG Mutant in a Genetically Stable Staphylococcus aureus Small-Colony Variant and Preliminary Assessment for Use as a Live-Attenuated Vaccine against Intrammamary Infections

Staphylococcus aureus is a leading cause of bovine intramammary infections (IMIs) that can evolve into difficult-to-treat chronic mastitis. To date, no vaccine formulation has shown high protective efficacy against S. aureus IMI, partly because this bacterium can efficiently evade the immune system....

Descripción completa

Detalles Bibliográficos
Autores principales: Côté-Gravel, Julie, Brouillette, Eric, Obradović, Nataša, Ster, Céline, Talbot, Brian G., Malouin, François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5113970/
https://www.ncbi.nlm.nih.gov/pubmed/27855187
http://dx.doi.org/10.1371/journal.pone.0166621
_version_ 1782468271791931392
author Côté-Gravel, Julie
Brouillette, Eric
Obradović, Nataša
Ster, Céline
Talbot, Brian G.
Malouin, François
author_facet Côté-Gravel, Julie
Brouillette, Eric
Obradović, Nataša
Ster, Céline
Talbot, Brian G.
Malouin, François
author_sort Côté-Gravel, Julie
collection PubMed
description Staphylococcus aureus is a leading cause of bovine intramammary infections (IMIs) that can evolve into difficult-to-treat chronic mastitis. To date, no vaccine formulation has shown high protective efficacy against S. aureus IMI, partly because this bacterium can efficiently evade the immune system. For instance, S. aureus small colony variants (SCVs) have intracellular abilities and can persist without producing invasive infections. As a first step towards the development of a live vaccine, this study describes the elaboration of a novel attenuated mutant of S. aureus taking advantage of the SCV phenotype. A genetically stable SCV was created through the deletion of the hemB gene, impairing its ability to adapt and revert to the invasive phenotype. Further attenuation was obtained through inactivation of gene vraG (SACOL0720) which we previously showed to be important for full virulence during bovine IMIs. After infection of bovine mammary epithelial cells (MAC-T), the double mutant (ΔvraGΔhemB) was less internalized and caused less cell destruction than that seen with ΔhemB and ΔvraG, respectively. In a murine IMI model, the ΔvraGΔhemB mutant was strongly attenuated, with a reduction of viable counts of up to 5-log10 CFU/g of mammary gland when compared to the parental strain. A complete clearance of ΔvraGΔhemB from glands was observed whereas mortality rapidly (48h) occurred with the wild-type strain. Immunization of mice using subcutaneous injections of live ΔvraGΔhemB raised a strong immune response as judged by the high total IgG titers measured against bacterial cell extracts and by the high IgG2a/IgG1 ratio observed against the IsdH protein. Also, ΔvraGΔhemB had sufficient common features with bovine mastitis strains so that the antibody response also strongly recognized strains from a variety of mastitis associated spa types. This double mutant could serve as a live-attenuated component in vaccines to improve cell-mediated immune responses against S. aureus IMIs.
format Online
Article
Text
id pubmed-5113970
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-51139702016-12-08 Characterization of a vraG Mutant in a Genetically Stable Staphylococcus aureus Small-Colony Variant and Preliminary Assessment for Use as a Live-Attenuated Vaccine against Intrammamary Infections Côté-Gravel, Julie Brouillette, Eric Obradović, Nataša Ster, Céline Talbot, Brian G. Malouin, François PLoS One Research Article Staphylococcus aureus is a leading cause of bovine intramammary infections (IMIs) that can evolve into difficult-to-treat chronic mastitis. To date, no vaccine formulation has shown high protective efficacy against S. aureus IMI, partly because this bacterium can efficiently evade the immune system. For instance, S. aureus small colony variants (SCVs) have intracellular abilities and can persist without producing invasive infections. As a first step towards the development of a live vaccine, this study describes the elaboration of a novel attenuated mutant of S. aureus taking advantage of the SCV phenotype. A genetically stable SCV was created through the deletion of the hemB gene, impairing its ability to adapt and revert to the invasive phenotype. Further attenuation was obtained through inactivation of gene vraG (SACOL0720) which we previously showed to be important for full virulence during bovine IMIs. After infection of bovine mammary epithelial cells (MAC-T), the double mutant (ΔvraGΔhemB) was less internalized and caused less cell destruction than that seen with ΔhemB and ΔvraG, respectively. In a murine IMI model, the ΔvraGΔhemB mutant was strongly attenuated, with a reduction of viable counts of up to 5-log10 CFU/g of mammary gland when compared to the parental strain. A complete clearance of ΔvraGΔhemB from glands was observed whereas mortality rapidly (48h) occurred with the wild-type strain. Immunization of mice using subcutaneous injections of live ΔvraGΔhemB raised a strong immune response as judged by the high total IgG titers measured against bacterial cell extracts and by the high IgG2a/IgG1 ratio observed against the IsdH protein. Also, ΔvraGΔhemB had sufficient common features with bovine mastitis strains so that the antibody response also strongly recognized strains from a variety of mastitis associated spa types. This double mutant could serve as a live-attenuated component in vaccines to improve cell-mediated immune responses against S. aureus IMIs. Public Library of Science 2016-11-17 /pmc/articles/PMC5113970/ /pubmed/27855187 http://dx.doi.org/10.1371/journal.pone.0166621 Text en © 2016 Côté-Gravel et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Côté-Gravel, Julie
Brouillette, Eric
Obradović, Nataša
Ster, Céline
Talbot, Brian G.
Malouin, François
Characterization of a vraG Mutant in a Genetically Stable Staphylococcus aureus Small-Colony Variant and Preliminary Assessment for Use as a Live-Attenuated Vaccine against Intrammamary Infections
title Characterization of a vraG Mutant in a Genetically Stable Staphylococcus aureus Small-Colony Variant and Preliminary Assessment for Use as a Live-Attenuated Vaccine against Intrammamary Infections
title_full Characterization of a vraG Mutant in a Genetically Stable Staphylococcus aureus Small-Colony Variant and Preliminary Assessment for Use as a Live-Attenuated Vaccine against Intrammamary Infections
title_fullStr Characterization of a vraG Mutant in a Genetically Stable Staphylococcus aureus Small-Colony Variant and Preliminary Assessment for Use as a Live-Attenuated Vaccine against Intrammamary Infections
title_full_unstemmed Characterization of a vraG Mutant in a Genetically Stable Staphylococcus aureus Small-Colony Variant and Preliminary Assessment for Use as a Live-Attenuated Vaccine against Intrammamary Infections
title_short Characterization of a vraG Mutant in a Genetically Stable Staphylococcus aureus Small-Colony Variant and Preliminary Assessment for Use as a Live-Attenuated Vaccine against Intrammamary Infections
title_sort characterization of a vrag mutant in a genetically stable staphylococcus aureus small-colony variant and preliminary assessment for use as a live-attenuated vaccine against intrammamary infections
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5113970/
https://www.ncbi.nlm.nih.gov/pubmed/27855187
http://dx.doi.org/10.1371/journal.pone.0166621
work_keys_str_mv AT cotegraveljulie characterizationofavragmutantinageneticallystablestaphylococcusaureussmallcolonyvariantandpreliminaryassessmentforuseasaliveattenuatedvaccineagainstintrammamaryinfections
AT brouilletteeric characterizationofavragmutantinageneticallystablestaphylococcusaureussmallcolonyvariantandpreliminaryassessmentforuseasaliveattenuatedvaccineagainstintrammamaryinfections
AT obradovicnatasa characterizationofavragmutantinageneticallystablestaphylococcusaureussmallcolonyvariantandpreliminaryassessmentforuseasaliveattenuatedvaccineagainstintrammamaryinfections
AT sterceline characterizationofavragmutantinageneticallystablestaphylococcusaureussmallcolonyvariantandpreliminaryassessmentforuseasaliveattenuatedvaccineagainstintrammamaryinfections
AT talbotbriang characterizationofavragmutantinageneticallystablestaphylococcusaureussmallcolonyvariantandpreliminaryassessmentforuseasaliveattenuatedvaccineagainstintrammamaryinfections
AT malouinfrancois characterizationofavragmutantinageneticallystablestaphylococcusaureussmallcolonyvariantandpreliminaryassessmentforuseasaliveattenuatedvaccineagainstintrammamaryinfections